Crizotinib efficacy after progression with entrectinib in ROS1-Positive lung cancer: a case report
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
CUREUS INC
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Crizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC). Although, entrectinib could be used after crizotinib, it is unknown whether crizotinib is effective after entrectinib. We report a case of NSCLC with ROS1 rearrangement that achieved a nearly complete response with crizotinib in the second-line treatment after progression with entrectinib. A 22-year-old Caucasian non-smoker female patient was diagnosed with stage IV non-squamous lung cancer with ROS1 positivity. We started on entrectinib as first-line therapy. Due to progression in the 10th month of treatment, entrectinib was stopped and crizotinib was started as a second -line treatment. At the end of the third month of the treatment, a nearly complete response was obtained in the follow-up imaging. The patient is still being followed up with crizotinib and is in the 15th month of treatment. Based on our experience, crizotinib can be an option as second-line therapy in patients who are treated with entrectinib in the first line, especially in patients without brain metastasis.
Açıklama
Anahtar Kelimeler
Targeted Therapy, Lung Cancer, Ros1, Entrectinib, Crizotinib
Kaynak
CUREUS JOURNAL OF MEDICAL SCIENCE
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
14
Sayı
8
Künye
Taban, H., Guven, D. C., & Kılıçkap, S. (2022). Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report. Cureus, 14(8).
